002872 ST天圣制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-2.082-4.355-4.065-2.939-18.770
总资产报酬率 ROA (%)-1.538-3.220-2.974-2.004-12.188
投入资产回报率 ROIC (%)-1.742-3.701-3.376-2.320-14.633

边际利润分析
销售毛利率 (%)45.05047.08356.57441.26429.093
营业利润率 (%)-16.681-16.152-13.955-8.279-41.600
息税前利润/营业总收入 (%)-15.346-15.196-12.495-6.170-41.704
净利润/营业总收入 (%)-15.478-16.176-15.083-9.820-41.038

收益指标分析
经营活动净收益/利润总额(%)92.005101.621125.389141.25731.842
价值变动净收益/利润总额(%)1.966-2.123-5.850-8.3950.481
营业外收支净额/利润总额(%)0.1051.214-0.701-12.0266.404

偿债能力分析
流动比率 (X)1.5991.5201.4691.9471.441
速动比率 (X)1.3161.2211.2341.6841.124
资产负债率 (%)26.53125.44526.36026.9480.345
带息债务/全部投入资本 (%)10.3906.8267.15511.13616.035
股东权益/带息债务 (%)793.7011,244.1261,188.356729.639479.127
股东权益/负债合计 (%)276.414292.414278.749270.393186.301
利息保障倍数 (X)-11.347-13.169-9.164-5.053-15.204

营运能力分析
应收账款周转天数 (天)87.74490.60092.643182.129203.091
存货周转天数 (天)151.134156.822174.443171.872123.307